Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 14/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5988937 | 1.00 | TBXAS1 (0.79) | TBXAS1 | |
| SCHEMBL2369806 | 1.00 | TBXAS1 (0.79) | TBXAS1 | |
| SCHEMBL2369290 | 1.00 | TBXAS1 (0.79) | TBXAS1 | |
| SCHEMBL7276173 | 1.00 | TBXAS1 (0.79) | TBXAS1 | |
| SCHEMBL3172850 | 1.00 | TBXAS1 (0.79) | TBXAS1 | |
| Hydrochloric Acid SCHEMBL3530240 | 0.98 | TBXAS1 (0.76) | TBXAS1 | |
| SCHEMBL139976 | 0.98 | TBXAS1 (0.75) | TBXAS1 | |
| Hydrochloric Acid SCHEMBL7276913 | 0.96 | TBXAS1 (0.72) | TBXAS1 | |
| Bromide SCHEMBL18941395 | 0.96 | TBXAS1 (0.72) | TBXAS1 | |
| SCHEMBL9253280 | 0.91 | TBXAS1 (0.71) | TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897995-B2 | Allophanate based dispersing agent | BASF SE (DE) | 2024-02-13 | — | — | US | claimed |
| US-20220275146-A1 | ALLOPHANATE BASED DISPERSING AGENT | BASF SE (DE) | 2022-09-01 | — | — | US | claimed |
| EP-3999570-A1 | ALLOPHANATE BASED DISPERSING AGENT | BASF SE (DE) | 2022-05-25 | — | — | EP | claimed |
| CN-114127150-A | Allophanate-based dispersants | 巴斯夫欧洲公司 | 2022-03-01 | — | — | CN | claimed |
| CN-110105332-A | A kind of preparation method for the adjustable compound ion liquid that shines | 山东大学 | 2019-08-09 | — | — | CN | claimed |
| EP-3141552-B1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM IND CO LTD (KR) | 2019-04-17 | — | — | EP | claimed |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025064718-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-11897995-B2 | Allophanate based dispersing agent | BASF SE (DE) | 2024-02-13 | — | — | US | disclosed |
| US-20220275146-A1 | ALLOPHANATE BASED DISPERSING AGENT | BASF SE (DE) | 2022-09-01 | — | — | US | disclosed |
| EP-3999570-A1 | ALLOPHANATE BASED DISPERSING AGENT | BASF SE (DE) | 2022-05-25 | — | — | EP | disclosed |
| CN-114127150-A | Allophanate-based dispersants | 巴斯夫欧洲公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-110105332-B | Preparation method of luminous adjustable composite ionic liquid | 山东大学 | 2020-05-22 | — | — | CN | disclosed |
| US-4610981-A | N-[(1H-imidazol-1-yl) and (1H-1,2,4-triazol-1-yl)-alkyl]benzenesulfonamides and thromboxane synthetase/antihypertensive compositions | AMERICAN CYANAMID COMPANY (US) | 1986-09-09 | — | — | US | disclosed |
| US-4576957-A | HYPOTENSIVE | AMERICAN CYANAMID COMPANY (US) | 1986-03-18 | — | — | US | disclosed |
| US-4568687-A | THROMBOXANE SYNTHETASE TNZYME INHIBITORS; HYPOTENSIVE AGENTS, CARDIOTONIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1986-02-04 | — | — | US | disclosed |
| US-4555519-A | Thromboxane synthetase enzyme inhibiting N-[(1H-imidazol-1-yl) and (1H-1,2,4-triazol-1-yl)alkyl]pyridinecarboxamides | AMERICAN CYANAMID COMPANY (US) | 1985-11-26 | — | — | US | disclosed |
| US-4489089-A | INHIBITION OF THE ENZYME THROMBOXANE SYNTHETASE | AMERICAN CYANAMID COMPANY (US) | 1984-12-18 | — | — | US | disclosed |
| EP-0127727-A2 | Substituted N-(omega-(1H-imidazol-1-yl)alkyl)) amides | AMERICAN CYANAMID COMPANY (US) | 1984-12-12 | — | — | EP | disclosed |
| EP-0117462-A2 | N-(2-4-(1H-imidazol-1-yl)alkyl)arylamides | AMERICAN CYANAMID COMPANY (US) | 1984-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | TBXAS1 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.